Big Pharma’s being squeezed by deal prices, both for discovery and development assets. And with new capital coming in to fund earlier-stage projects, deals will only get more expensive. But forward thinking Big Pharma R&D executives are beginning to realize that the seller’s market can work to their advantage, too.
